(Reuters) – Israeli firm Oramed says insulin pill succeeds in mid-stage type 2 diabetes trial and if successful in next phase could make daily insulin injections a thing of the past. Sharon Reich reports.
More than 400 million people around the world suffer from diabetes. Until recently it was thought that Type 2 diabetes was an adult onset condition. However, the WHO says it’s now occurring increasingly in children too.
So news that Israeli drugmaker Oramed Pharmaceuticals Inc
has developed an experimental oral insulin that safely reduces night-time blood glucose levels in type 2 patients is promising.
Oramed’s chief executive Nadav Kidron says the drug’s mid-stage trial shows there could be a healthier alternative to insulin injections.
NADAV KIDRON, CHIEF EXECUTIVE OFFICER AT ORAMED PHARMACEUTICALS:
“When you give it as an injection, it goes straight into the blood stream but when we give it orally, it goes first, it’s passed to the liver . . . and the liver is the organ that regulates the secretion of the insulin into the blood stream so that’s why it’s the healthier, more physiological way to treat diabetes through oral insulin.”
The study is surprising because until now many researchers thought insulin couldn’t survive the onslaught of digestive juices.
Oramed says the new drug uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone.
The results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.